And quantifying how the move from copays to coinsurance is driving up OOPs on ‘negotiated’ drugs
And Mesoblast unveils the price for its stem-cell therapy with a noteworthy amount of transparency around value
Plus a couple of links on Elon Musk’s heel turn on health care
But UCB -- bucking the trend -- released its annual numbers: net prices are down, rebates are up
Plus some musings on when or how the 340B debate intersects with legislative pushes around Medicaid
And a J&J lawsuit over biosimilars is the first shot in the war against PBM-backed pseudo-pharma companies
Plus a look at how the price of SpringWorks’ Gomelki was disclosed
Spring might be around the corner, but the news on 340B, IRA, gene therapies, insulin, and more continues to accumulate
And the attacks on Antonio Ciaccia continue, but his work remains unimpeached
And shadowy forces are coming for Antonio Ciaccia ... suggesting that Antonio is on to something
And we have results from the how-long-will-Kennedy-last poll!
And his tenure is starting with a mandate to create a new report that probably won't generate the answers it needs to generate
